BACKGROUND: The type 3 secretion protein PcrV and Psl exopolysaccharide are promising therapeutic antibody targets against Pseudomonas aeruginosa. We examined P. aeruginosa bloodstream infection (BSI) isolates for the ability to express PcrV and Psl and evaluated corresponding patient serum for active titers to these targets. METHODS: We identified 114 patients with acute P. aeruginosa BSI; 56 cases were accompanied by acute sera. Serum was evaluated for PcrV- and Psl-specific immunoglobulin G (IgG) and for cytotoxicity and opsonophagocytosis. Isolates were evaluated for susceptibility to antibiotics, expression of PcrV and Psl, and susceptibility to the anti-PcrV/Psl bispecific antibody and clinical candidate MEDI3902. RESULTS: In-hospital mortality for patients with P. aeruginosa BSI was 39%. A total of 26% of isolates were resistant to ≥3 antibiotic classes. Although PcrV and/or Psl were detected in 99% of isolates, a majority of patients lacked active titers to PcrV (100%) and Psl (98%). In addition, MEDI3902 was active against all tested isolates. CONCLUSIONS: A vast majority of P. aeruginosa BSI isolates express PcrV and Psl; however, patient sera most often lacked IgG and functionally active responses to these targets. These results suggest that therapies directed at PcrV and Psl could be a promising approach for combating P. aeruginosa bloodstream infections.
BACKGROUND: The type 3 secretion protein PcrV and Psl exopolysaccharide are promising therapeutic antibody targets against Pseudomonas aeruginosa. We examined P. aeruginosa bloodstream infection (BSI) isolates for the ability to express PcrV and Psl and evaluated corresponding patient serum for active titers to these targets. METHODS: We identified 114 patients with acute P. aeruginosa BSI; 56 cases were accompanied by acute sera. Serum was evaluated for PcrV- and Psl-specific immunoglobulin G (IgG) and for cytotoxicity and opsonophagocytosis. Isolates were evaluated for susceptibility to antibiotics, expression of PcrV and Psl, and susceptibility to the anti-PcrV/Psl bispecific antibody and clinical candidate MEDI3902. RESULTS: In-hospital mortality for patients with P. aeruginosa BSI was 39%. A total of 26% of isolates were resistant to ≥3 antibiotic classes. Although PcrV and/or Psl were detected in 99% of isolates, a majority of patients lacked active titers to PcrV (100%) and Psl (98%). In addition, MEDI3902 was active against all tested isolates. CONCLUSIONS: A vast majority of P. aeruginosa BSI isolates express PcrV and Psl; however, patient sera most often lacked IgG and functionally active responses to these targets. These results suggest that therapies directed at PcrV and Psl could be a promising approach for combating P. aeruginosa bloodstream infections.
Authors: Carlos E Milla; James F Chmiel; Frank J Accurso; Donald R VanDevanter; Michael W Konstan; Geoffrey Yarranton; David E Geller Journal: Pediatr Pulmonol Date: 2013-09-09
Authors: Bruno François; Charles-Edouard Luyt; Anthony Dugard; Michel Wolff; Jean-Luc Diehl; Samir Jaber; Jean-Marie Forel; Denis Garot; Eric Kipnis; Alexandre Mebazaa; Benoit Misset; Antoine Andremont; Marie-Cécile Ploy; Alan Jacobs; Geoffrey Yarranton; Tillman Pearce; Jean-Yves Fagon; Jean Chastre Journal: Crit Care Med Date: 2012-08 Impact factor: 7.598
Authors: Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey Journal: J Cyst Fibros Date: 2012-09-01 Impact factor: 5.482
Authors: Kun Zhao; Boo Shan Tseng; Bernard Beckerman; Fan Jin; Maxsim L Gibiansky; Joe J Harrison; Erik Luijten; Matthew R Parsek; Gerard C L Wong Journal: Nature Date: 2013-05-08 Impact factor: 49.962
Authors: Donald T Moir; Nicholas O Bowlin; Bryan J Berube; Jaden Yabut; Debra M Mills; Giang T Nguyen; Zachary D Aron; John D Williams; Joan Mecsas; Alan R Hauser; Terry L Bowlin Journal: J Bacteriol Date: 2020-08-25 Impact factor: 3.490
Authors: Joshua T Thaden; Lawrence P Park; Stacey A Maskarinec; Felicia Ruffin; Vance G Fowler; David van Duin Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Valerie A Ray; Preston J Hill; C Kendall Stover; Sashwati Roy; Chandan K Sen; Li Yu; Daniel J Wozniak; Antonio DiGiandomenico Journal: Sci Rep Date: 2017-11-22 Impact factor: 4.379
Authors: Ami Patel; Antonio DiGiandomenico; Ashley E Keller; Trevor R F Smith; Daniel H Park; Stephanie Ramos; Katherine Schultheis; Sarah T C Elliott; Janess Mendoza; Kate E Broderick; Megan C Wise; Jian Yan; Jingjing Jiang; Seleeke Flingai; Amir S Khan; Kar Muthumani; Laurent Humeau; Lily I Cheng; Leslie Wachter-Rosati; C Kendall Stover; Niranjan Y Sardesai; David B Weiner Journal: Nat Commun Date: 2017-09-21 Impact factor: 14.919
Authors: Hoan N Le; Josiane Silva Quetz; Vuvi G Tran; Vien T M Le; Fábio Aguiar-Alves; Marcos G Pinheiro; Lily Cheng; Li Yu; Bret R Sellman; Charles K Stover; Antonio DiGiandomenico; Binh An Diep Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Henrik Almblad; Trevor E Randall; Fanny Liu; Katherine Leblanc; Ryan A Groves; Weerayuth Kittichotirat; Geoffrey L Winsor; Nicolas Fournier; Emily Au; Julie Groizeleau; Jacquelyn D Rich; Yuefei Lou; Elise Granton; Laura K Jennings; Larissa A Singletary; Tara M L Winstone; Nathan M Good; Roger E Bumgarner; Michael F Hynes; Manu Singh; Maria Silvina Stietz; Fiona S L Brinkman; Ayush Kumar; Ann Karen Cornelia Brassinga; Matthew R Parsek; Boo Shan Tseng; Ian A Lewis; Bryan G Yipp; Justin L MacCallum; Joe Jonathan Harrison Journal: Nat Commun Date: 2021-03-31 Impact factor: 14.919